Work

Rapid progress in our understanding of COVID-19 vaccine allergy: A cause for optimism, not hesitancy

Year: 2022

Type: review

Source: Journal of Allergy and Clinical Immunology

DOI: 10.1016/j.jaci.2022.03.023

Authors: Aleena Banerji, Allison E. Norton, Kimberly G. Blumenthal, Cosby A. Stone, Elizabeth Phillips

Institutions: Harvard University, Massachusetts General Hospital, Monroe Carell Jr. Children's Hospital, Vanderbilt University Medical Center

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, Agency for Healthcare Research and Quality, National Human Genome Research Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases

Awards: G129402337, G1991070941, G3025672635, Clinical Informatics to Advance Epidemiology and Pharmacogenetics of Serious Cutaneous Adverse Drug Reactions, The Clinical and Economic Impact of Penicillin Allergy, Stevens-Johnson syndrome/toxic epidermal necrolysis 2021: Collaboration, Innovation and Community, Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivors, Immune Tolerance Network, Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study), NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

OpenAlex ID: W4223542162

FWCI: 0.73

Cites: 31

Cited by: 20

Related to: 10